Lysodren, known generically as mitotane, is a medication primarily used in the treatment of adrenal gland tumors, specifically those affecting the cortex, such as adrenocortical carcinoma. It functions by exerting a cytotoxic effect on the adrenal cortex, which helps in reducing the production of adrenal hormones and inhibiting tumor growth. Lysodren is often prescribed for patients with inoperable, recurrent, or metastatic adrenal gland tumors. Its use requires careful monitoring due to its potential side effects, which can include gastrointestinal disturbances, neurological effects, and adrenal insufficiency, necessitating regular follow-up and possibly adjustments in dosage. Given its specific action on the adrenal glands, Lysodren plays a crucial role in the management of certain types of adrenal gland cancers, offering a therapeutic option for controlling hormone production and slowing tumor progression.